Concentrations of Cysteinyl Leukotrienes in Various Biological Fluids of Children with Bronchial Asthma, Atopic Dermatitis and Food Protein Induced Enterocolitis

Clinical manifestation of food allergy is characterized by polymorphic cutaneous, respiratory and gastrointestinal syndromes. Leukotrienes occupy a key place in the pathogenesis of a wide range of inflammatory diseases, including bronchial asthma, allergic rhinitis, atopic dermatitis, hives, allergic conjunctivitis, atherosclerotic cardio-vascular lesions system, inflammatory bowel disease, multiple sclerosis, cancer, etc. Better understanding of general pathophysiological mechanisms of allergic realization put the focus on the studying of cysteinyl leukotrienes biological effects in infants with atopic dermatitis and food-protein induced enterocolitis important.Aim. To optimize the diagnosis of allergic lesions of the gastrointestinal tract in children.Methods. The study was conducted in the allergy center and children clinic of the «Institute Pediatrics, Obstetrics and Gynecology named after academician O. Lukyanova of NAMS of Ukraine». Children were included from September 2017 to June 2018.We examined 60 patients aged from 3 months to 3 years old, including 22 patients with atopic dermatitis, 18 children with food-protein induced enterocolitis, 8 patients with bronchial asthma in the stage of aggravation and 12 practically healthy children (control group).Medical examination have been perfomed, general IG E and specific serum IG E were defined by ImmunoCAP (Phadia, 100), as well as concentrations of cysteinyl leukotrienes (LTB4, LTC4, LTE4) in biological liquids (serum, saliva, urine) using immunoenzyme method using the production sets of the "Enzolifescience" (USA) company on the analyzer-photometer Multiskan Plus "Labsystems". The results of the received data were processed statistically. The probability of differences was estimated with Student's t-test and Tau Kendall rank correlation test. The difference was considered significant at p <0.05.Results. A significant increase in the concentrations of cysteinyl leukotrienes (C4, D4, E4) in the blood, urine and saliva was found in infants with allergic skin diseases, gastro-intestinal and respiratory tract surveyed during manifestation the disease compared with the control group.Comparison of concentrations of leukotrienes in urine and saliva of children with atopic dermatitis (AD), food-protein induced enterocolitis (FPIE) and asthma did not find credible. However, in the serum of patients with asthma, the concentration of cysteinyl leukotrienes was significantly higher (703.9±68.7) pg / ml than in children with enterocolitis induced by dietary proteins (509.3±57.4) pg / ml and significantly did not differ from patients with atopic dermatitis (695.2±46.3) pg / ml.According to the results of Kendall Tau correlation test, no significant Spearman rank correlation was found between the cysteinyl leukotrienes concentration in blood and urine – r=0.14 (p>0.05), blood and saliva r=0.07 (p>0.05), urine and saliva r=–0.52 (p>0.05).Conclusions. Increase in cysteinyl leukotrienes concentrations in serum, urine and saliva of children of early age with allergic skin diseases, respiratory and gastrointestinal tract was found. The absence of significant Spearman rank correlation between concentrations of leukotrienes in blood and urine, blood and saliva, saliva and urine shows that it is possible to select any biological fluid, saliva or urine, as a non-invasive way to determine the leukotriene concentrations for monitoring activity of allergic inflammation

Concentrations of Cysteinyl Leukotrienes in Various Biological Fluids of Children with Bronchial Asthma, Atopic Dermatitis and Food Protein Induced Enterocolitis

Clinical manifestation of food allergy is characterized by polymorphic cutaneous, respiratory and gastrointestinal syndromes. Leukotrienes occupy a key place in the pathogenesis of a wide range of inflammatory diseases, including bronchial asthma, allergic rhinitis, atopic dermatitis, hives, allergic conjunctivitis, atherosclerotic cardio-vascular lesions system, inflammatory bowel disease, multiple sclerosis, cancer, etc. Better understanding of general pathophysiological mechanisms of allergic realization put the focus on the studying of cysteinyl leukotrienes biological effects in infants with atopic dermatitis and food-protein induced enterocolitis important.Aim. To optimize the diagnosis of allergic lesions of the gastrointestinal tract in children.Methods. The study was conducted in the allergy center and children clinic of the «Institute Pediatrics, Obstetrics and Gynecology named after academician O. Lukyanova of NAMS of Ukraine». Children were included from September 2017 to June 2018.We examined 60 patients aged from 3 months to 3 years old, including 22 patients with atopic dermatitis, 18 children with food-protein induced enterocolitis, 8 patients with bronchial asthma in the stage of aggravation and 12 practically healthy children (control group).Medical examination have been perfomed, general IG E and specific serum IG E were defined by ImmunoCAP (Phadia, 100), as well as concentrations of cysteinyl leukotrienes (LTB4, LTC4, LTE4) in biological liquids (serum, saliva, urine) using immunoenzyme method using the production sets of the "Enzolifescience" (USA) company on the analyzer-photometer Multiskan Plus "Labsystems". The results of the received data were processed statistically. The probability of differences was estimated with Student's t-test and Tau Kendall rank correlation test. The difference was considered significant at p <0.05.Results. A significant increase in the concentrations of cysteinyl leukotrienes (C4, D4, E4) in the blood, urine and saliva was found in infants with allergic skin diseases, gastro-intestinal and respiratory tract surveyed during manifestation the disease compared with the control group.Comparison of concentrations of leukotrienes in urine and saliva of children with atopic dermatitis (AD), food-protein induced enterocolitis (FPIE) and asthma did not find credible. However, in the serum of patients with asthma, the concentration of cysteinyl leukotrienes was significantly higher (703.9±68.7) pg / ml than in children with enterocolitis induced by dietary proteins (509.3±57.4) pg / ml and significantly did not differ from patients with atopic dermatitis (695.2±46.3) pg / ml.According to the results of Kendall Tau correlation test, no significant Spearman rank correlation was found between the cysteinyl leukotrienes concentration in blood and urine – r=0.14 (p>0.05), blood and saliva r=0.07 (p>0.05), urine and saliva r=–0.52 (p>0.05).Conclusions. Increase in cysteinyl leukotrienes concentrations in serum, urine and saliva of children of early age with allergic skin diseases, respiratory and gastrointestinal tract was found. The absence of significant Spearman rank correlation between concentrations of leukotrienes in blood and urine, blood and saliva, saliva and urine shows that it is possible to select any biological fluid, saliva or urine, as a non-invasive way to determine the leukotriene concentrations for monitoring activity of allergic inflammation

Leukotriene mechanisms of allergic enterocolitis pathogenesis in young children

Purpose of the study was to determine the parameters of lipid mediators of allergic inflammation (cysteinyl leukotrienes C4, D4, E4) by enzyme immunoassay in serum, saliva, urine of young children with allergic enterocolitis.Materials and methods. 40 patients aged from 3 months to 3 years (mean age - (19.9 ± 2.7) months) were examined, among them 20 children with allergic enterocolitis, 10 patients with asthma at the acute stage and 10 healthy babies. Clinical, allergological, endoscopic examination and concentrations of cysteinyl leukotrienes (LTB4, LTC4, LTE4) determination in the biological fluids (blood serum, saliva, urine) using the enzyme immunoassay kits (Enzo Life Science, USA) on a Multiskan photometer Plus “Labsystems” were conducted. The obtained data results were processed statistically. Significance of differences was assessed using Student's t-test and Kendall's tau rank correlation analysis. Difference with a p value 0.05), blood and saliva τ = 0.07 (p>0.05), urine and saliva τ = -0.52 (P > 0.05).Conclusions. An increase in cysteinyl leukotrienes concentration in blood serum, urine, saliva was found in young children with allergic enterocolitis in comparison with the control group. The absence of a significant rank correlation between leukotrienes concentration in the blood and urine, blood and saliva, saliva and urine indicates that any biological fluid, in particular saliva or urine, could be selected as a non-invasive method for determination of leukotrienes concentration to monitor the activity of allergic inflammation

Shared Genetics of Multiple System Atrophy and Inflammatory Bowel Disease

BACKGROUND: Multiple system atrophy (MSA) is a rare neurodegenerative disease characterized by intracellular accumulations of α-synuclein and nerve cell loss in striatonigral and olivopontocerebellar structures. Epidemiological and clinical studies have reported potential involvement of autoimmune mechanisms in MSA pathogenesis. However, genetic etiology of this interaction remains unknown. We aimed to investigate genetic overlap between MSA and 7 autoimmune diseases and to identify shared genetic loci. METHODS: Genome-wide association study summary statistics of MSA and 7 autoimmune diseases were combined in cross-trait conjunctional false discovery rate analysis to explore overlapping genetic background. Expression of selected candidate genes was compared in transgenic MSA mice and wild-type mice. Genetic variability of candidate genes was further investigated using independent whole-exome genotyping data from large cohorts of MSA and autoimmune disease patients and healthy controls. RESULTS: We observed substantial polygenic overlap between MSA and inflammatory bowel disease and identified 3 shared genetic loci with leading variants upstream of the DENND1B and RSP04 genes, and in intron of the C7 gene. Further, the C7 gene showed significantly dysregulated expression in the degenerating midbrain of transgenic MSA mice compared with wild-type mice and had elevated burden of protein-coding variants in independent MSA and inflammatory bowel disease cohorts. CONCLUSION: Our study provides evidence of shared genetic etiology between MSA and inflammatory bowel disease with an important role of the C7 gene in both phenotypes, with the implication of immune and gut dysfunction in MSA pathophysiology. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC. on behalf of International Parkinson and Movement Disorder Society

Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers

Altres ajuts: European Alzheimer DNA BioBank, EADB; EU Joint Programme, Neurodegenerative Disease Research (JPND); Neurodegeneration research program of Amsterdam Neuroscience; Stichting Alzheimer Nederland; Stichting VUmc fonds; Stichting Dioraphte; JPco-fuND FP-829-029 (ZonMW projectnumber 733051061); Dutch Federation of University Medical Centers; Dutch Government (from 2007-2011); JPND EADB grant (German Federal Ministry of Education and Research (BMBF) grant: 01ED1619A); German Research Foundation (DFG RA 1971/6-1, RA1971/7-1, RA 1971/8-1); Grifols SA; Fundación bancaria 'La Caixa'; Fundació ACE; CIBERNED; Fondo Europeo de Desarrollo Regional (FEDER-'Una manera de hacer Europa'); NIH (P30AG066444, P01AG003991); Alzheimer Research Foundation (SAO-FRA), The Research Foundation Flanders (FWO), and the University of Antwerp Research Fund. FK is supported by a BOF DOCPRO fellowship of the University of Antwerp Research Fund; Siemens Healthineers; Valdecilla Biobank (PT17/0015/0019); Academy of Finland (338182); German Center for Neurodegenerative Diseases (DZNE); German Federal Ministry of Education and Research (BMBF 01G10102, 01GI0420, 01GI0422, 01GI0423, 01GI0429, 01GI0431, 01GI0433, 04GI0434, 01GI0711); ZonMW (#73305095007); Health~Holland, Topsector Life Sciences & Health (PPP-allowance #LSHM20106); Hersenstichting; Edwin Bouw Fonds; Gieskes-Strijbisfonds; NWO Gravitation program BRAINSCAPES: A Roadmap from Neurogenetics to Neurobiology (NWO: 024.004.012); Swedish Alzheimer Foundation (AF-939988, AF-930582, AF-646061, AF-741361); Dementia Foundation (2020-04-13, 2021-04-17); Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALF 716681); Swedish Research Council (11267, 825-2012-5041, 2013-8717, 2015-02830, 2017-00639, 2019-01096); Swedish Research Council for Health, Working Life and Welfare (2001-2646, 2001-2835, 2001-2849, 2003-0234, 2004-0150, 2005-0762, 2006-0020, 2008-1229, 2008-1210, 2012-1138, 2004-0145, 2006-0596, 2008-1111, 2010-0870, 2013-1202, 2013-2300, 2013-2496); Swedish Brain Power, Hjärnfonden, Sweden (FO2016-0214, FO2018-0214, FO2019-0163); Alzheimer's Association Zenith Award (ZEN-01-3151); Alzheimer's Association Stephanie B. Overstreet Scholars (IIRG-00-2159); Alzheimer's Association (IIRG-03-6168, IIRG-09-131338); Bank of Sweden Tercentenary Foundation; Swedish state under the agreement between the Swedish government and the county councils, the ALF-agreement (ALFGBG-81392, ALFGBG-771071); Swedish Alzheimer Foundation (AF-842471, AF-737641, AF-939825); Swedish Research Council (2019-02075); Swedish Research Council (2016-01590); BRAINSCAPES: A Roadmap from Neurogenetics to Neurobiology (024.004.012); Swedish Research Council (2018-02532); Swedish State Support for Clinical Research (ALFGBG-720931); Alzheimer Drug Discovery Foundation (ADDF), USA (201809-2016862); UK Dementia Research Institute at UCL; Swedish Research Council (#2017-00915); Alzheimer Drug Discovery Foundation (ADDF), USA (#RDAPB-201809-2016615); Swedish Alzheimer Foundation (#AF-742881); Hjärnfonden, Sweden (#FO2017-0243); Swedish state under the agreement between the Swedish government and the County Councils, the ALF-agreement (#ALFGBG-715986); National Institute of Health (NIH), USA, (#1R01AG068398-01); Alzheimer's Association 2021 Zenith Award (ZEN-21-848495); National Institutes of Health (R01AG044546, R01AG064877, RF1AG053303, R01AG058501, U01AG058922, RF1AG058501, R01AG064614); Chuck Zuckerberg Initiative (CZI).Amyloid-beta 42 (Aβ42) and phosphorylated tau (pTau) levels in cerebrospinal fluid (CSF) reflect core features of the pathogenesis of Alzheimer's disease (AD) more directly than clinical diagnosis. Initiated by the European Alzheimer & Dementia Biobank (EADB), the largest collaborative effort on genetics underlying CSF biomarkers was established, including 31 cohorts with a total of 13,116 individuals (discovery n = 8074; replication n = 5042 individuals). Besides the APOE locus, novel associations with two other well-established AD risk loci were observed; CR1 was shown a locus for Aβ42 and BIN1 for pTau. GMNC and C16orf95 were further identified as loci for pTau, of which the latter is novel. Clustering methods exploring the influence of all known AD risk loci on the CSF protein levels, revealed 4 biological categories suggesting multiple Aβ42 and pTau related biological pathways involved in the etiology of AD. In functional follow-up analyses, GMNC and C16orf95 both associated with lateral ventricular volume, implying an overlap in genetic etiology for tau levels and brain ventricular volume

New insights into the genetic etiology of Alzheimer's disease and related dementias.

Characterization of the genetic landscape of Alzheimer's disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/'proxy' AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele

New insights into the genetic etiology of Alzheimer's disease and related dementias

Characterization of the genetic landscape of Alzheimer's disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/'proxy' AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele

Multiancestry analysis of the HLA locus in Alzheimer’s and Parkinson’s diseases uncovers a shared adaptive immune response mediated by HLA-DRB1*04 subtypes

Across multiancestry groups, we analyzed Human Leukocyte Antigen (HLA) associations in over 176,000 individuals with Parkinson’s disease (PD) and Alzheimer’s disease (AD) versus controls. We demonstrate that the two diseases share the same protective association at the HLA locus. HLA-specific fine-mapping showed that hierarchical protective effects of HLA-DRB1*04 subtypes best accounted for the association, strongest with HLA-DRB1*04:04 and HLA-DRB1*04:07, and intermediary with HLA-DRB1*04:01 and HLA-DRB1*04:03. The same signal was associated with decreased neurofibrillary tangles in postmortem brains and was associated with reduced tau levels in cerebrospinal fluid and to a lower extent with increased Aβ42. Protective HLA-DRB1*04 subtypes strongly bound the aggregation-prone tau PHF6 sequence, however only when acetylated at a lysine (K311), a common posttranslational modification central to tau aggregation. An HLA-DRB1*04-mediated adaptive immune response decreases PD and AD risks, potentially by acting against tau, offering the possibility of therapeutic avenues

Пробіотична корекція функціональних захворювань шлунково-кишкового тракту у дітей

The problem of functional diseases of the gastrointestinal tract (FD GIT) continues to be relevant. In patients with FD GIT, the quality of life and adaptive properties are reduced. To date, a hallmark of the treatment for gastrointestinal diseases is probiotics. The efficacy of probiotics in the prevention of acute gastrointestinal diseases, including using in the neonatal period, antibiotic-associated diarrhea, nosocomial infections, management of various functional disorders of the digestive tract has been proved. In Ukraine, probiotics containing live lyophilized bacteria, namely Bifidobacterium animalis subsp. lactis BB–12, are successfully used to treat conditions associated with impaired intestinal microflora composition, including in newborns.Проблема функциональных заболеваний желудочно-кишечного тракта (ФЗ ЖКТ) не утрачивает актуальности. У больных ФЗ ЖКТ снижается качество жизни, уменьшаются адаптивные способности организма. Сегодня важной составляющей терапии заболеваний ЖКТ являются пробиотики. Доказана эффективность пробиотиков в профилактике острых желудочно-кишечных заболеваний, в том числе неонатального периода, антибиотикассоциированной диареи, внутрибольничных инфекций, коррекции различных функциональных расстройств пищеварительного тракта. В Украине для лечения состояний, связанных с нарушением состава микрофлоры кишечника, в том числе у новорожденных, успешно применяются пробиотики, содержащие живые лиофилизированные Bifidobacterium animalis subsp. lactis BB—12.Проблема функціональних захворювань шлунково-кишкового тракту (ФЗ ШКТ) не втрачає актуальності. У хворих на ФЗ ШКТ знижується якість життя, зменшуються адаптивні властивості організму. Сьогодні важливою складовою терапії захворювань ШКТ є пробіотики. Доведена ефективність пробіотиків у профілактиці гострих шлунково-кишкових захворювань, у тому числі неонатального періоду, антибіотикасоційованої діареї, внутрішньолікарняних інфекцій, корекції різних функціональних розладів травного тракту. В Україні для лікування станів, пов'язаних з порушенням складу мікрофлори кишечника, у тому числі у новонароджених, успішно застосовуються пробіотики, що містять живі ліофілізовані Bifidobacterium animalis subsp. lactis BB-12

Лейкотрієнові механізми патогенезу алергічного ентероколіту в дітей раннього віку

Purpose of the study was to determine the parameters of lipid mediators of allergic inflammation (cysteinyl leukotrienes C4, D4, E4) by enzyme immunoassay in serum, saliva, urine of young children with allergic enterocolitis.Materials and methods. 40 patients aged from 3 months to 3 years (mean age - (19.9 ± 2.7) months) were examined, among them 20 children with allergic enterocolitis, 10 patients with asthma at the acute stage and 10 healthy babies. Clinical, allergological, endoscopic examination and concentrations of cysteinyl leukotrienes (LTB4, LTC4, LTE4) determination in the biological fluids (blood serum, saliva, urine) using the enzyme immunoassay kits (Enzo Life Science, USA) on a Multiskan photometer Plus “Labsystems” were conducted. The obtained data results were processed statistically. Significance of differences was assessed using Student's t-test and Kendall's tau rank correlation analysis. Difference with a p value <0.05 was considered statistically significant.Results. A significant increase in cysteinyl leukotrienes (C4, D4, E4) concentration in the blood, urine and saliva of young children with allergic enterocolitis and bronchial asthma was observed during the disease manifestation, compared with the control group. Comparative characteristics of the leukotrienes concentration in urine and saliva of children with allergic enterocolitis and asthma did not reveal significant differences, however their concentration was significantly higher (703.9 ± 68.7) pg/ml in the serum of patients with asthma, than in children with allergic enterocolitis (509.3 ± 57.4) pg/ml. According to the results of the Kendall’s tau correlation analysis, there was no significant rank correlation between the concentrations of cysteinyl leukotrienes in blood and urine - τ = 0.14 (P > 0.05), blood and saliva τ = 0.07 (p>0.05), urine and saliva τ = -0.52 (P > 0.05).Conclusions. An increase in cysteinyl leukotrienes concentration in blood serum, urine, saliva was found in young children with allergic enterocolitis in comparison with the control group. The absence of a significant rank correlation between leukotrienes concentration in the blood and urine, blood and saliva, saliva and urine indicates that any biological fluid, in particular saliva or urine, could be selected as a non-invasive method for determination of leukotrienes concentration to monitor the activity of allergic inflammation.  Цель работы – определить показатели липидных медиаторов аллергического воспаления (цистеинилових лейкотриенов C4, D4, E4) методом иммуноферментного анализа в сыворотке крови, слюне, моче детей раннего возраста с аллергическим энтероколитом.Материалы и методы. Обследованы 40 пациентов в возрасте от 3 месяцев до 3 лет (средний возраст – 19,9 ± 2,7 мес.), среди которых 20 детей с аллергическим энтероколитом, 10 пациентов с бронхиальной астмой в стадии обострения и 10 здоровых малышей. Проведено клиническое, аллергологическое, по показаниям – эндоскопическое исследование и определение концентраций цистеиниловых лейкотриенов (ЛTB4, ЛTC4, ЛTE4) в биологических жидкостях (сыворотка крови, слюна, моча) иммуноферментным методом с использованием наборов производства компании «Enzo Life Science» (США) на анализаторе-фотометре Multiskan Plus «Labsystems». Результаты обработаны статистически. Вероятность различий оценивали с помощью t-критерия Стьюдента и рангового корреляционного анализа Тау Кендалла. Разницу считали достоверной при р < 0,05.Результаты. Установлено достоверное увеличение концентрации цистеиниловых лейкотриенов (C4, D4, E4) в крови, мочи и слюне детей раннего возраста с аллергическим энтероколитом и бронхиальной астмой, обследованных в период манифестации заболевания, по сравнению с группой контроля. Сравнительная характеристика концентрации лейкотриенов мочи и слюны детей с аллергическим энтероколитом и астмой не показала достоверных различий, однако в сыворотке крови пациентов с астмой их концентрация достоверно выше (703,9 ± 68,7 пг/мл), чем у детей с аллергическим энтероколитом (509,3 ± 57,4 пг/мл). По результатам корреляционного анализа Тау Кендалла не установлена значимая ранговая корреляционная связь между концентрациями цистеиниловых лейкотриенов в крови и моче – τ = 0,14 (р > 0,05), крови и слюне – τ = 0,07 (р > 0,05), моче и слюне – τ = -0,52 (р > 0,05). Выводы. Установлено увеличение концентрации цистеиниловых лейкотриенов в сыворотке крови, моче, слюне детей раннего возраста с аллергическим энтероколитом по сравнению с группой контроля. Отсутствие значимой ранговой корреляционной связи между концентрациями лейкотриенов в крови и моче, крови и слюне, слюне и моче свидетельствует о возможности выбора любой биологической жидкости, в частности слюны или мочи как неинвазивного способа определения концентраций лейкотриенов для проведения мониторинга активности аллергического воспаления. Мета роботи – визначити показники ліпідних медіаторів алергічного запалення (цистеїнілових лейкотрієнів C4, D4, E4) методом імуноферментного аналізу в сироватці крові, слині, сечі дітей раннього віку з алергічним ентероколітом.Матеріали та методи. Обстежили 40 пацієнтів віком від 3 місяців до 3 років (середній вік – 19,9 ± 2,7 місяця), серед них 20 дітей з алергічним ентероколітом, 10 пацієнтів із бронхіальною астмою у стадії загострення, 10 здорових малюків. Виконали загальноклінічне, алергологічне, за показаннями – ендоскопічне дослідження, визначили концентрації цистеїнілових лейкотрієнів (ЛTB4, ЛTC4, ЛTE4) в біологічних рідинах (сироватка крові, слина, сеча) імуноферментним методом із використанням наборів виробництва компанії «Enzo Life Science» (США) за допомогою аналізатора-фотометра Multiskan Plus «Labsystems». Результати опрацювали статистично. Вірогідність різниць оцінювали за допомогою t-критерію Стьюдента та рангового кореляційного аналізу Тау Кендала. Різницю вважали вірогідною при р < 0,05.Результати. Встановили вірогідне збільшення концентрації цистеїнілових лейкотрієнів (C4, D4, E4) у крові, сечі та слині дітей раннього віку з алергічним ентероколітом і бронхіальною астмою, яких обстежили в період маніфестації захворювання, порівняно з групою контролю. Порівняльна характеристика концентрації лейкотрієнів сечі та слини дітей з алергічним ентероколітом та астмою не показала вірогідних відмінностей, однак у сироватці крові пацієнтів з астмою їхня концентрація була вірогідно більшою (703,9 ± 68,7 пг/мл), ніж у малюків з алергічним ентероколітом (509,3 ± 57,4 пг/мл). У результаті кореляційного аналізу Тау Кендала не виявили значущого рангового кореляційного зв’язку між концентраціями цистеїнілових лейкотрієнів у крові та сечі – τ = 0,14 (р > 0,05), крові та слині – τ = 0,07 (р > 0,05), сечі та слині – τ = -0,52 (р > 0,05).Висновки. Встановили збільшення концентрації цистеїнілових лейкотрієнів у сироватці крові, сечі, слині дітей раннього віку з алергічним ентероколітом порівняно з групою контролю. Відсутність значущого рангового кореляційного зв’язку між концентраціями лейкотрієнів у крові та сечі, крові та слині, слині та сечі свідчить про можливість вибору будь-якої біологічної рідини, зокрема слини або сечі як неінвазивного способу визначення концентрацій лейкотрієнів для моніторингу активності алергічного запалення